---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Definition and etiology"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Definition and etiology. Topics: Definition of non-muscle-invasive bladder cancer, Definition and clinical classification of carcinoma in situ, High-risk and very high-risk NMIBC: EAU prognostic factor risk groups, Definition of BCG-unresponsive disease: FDA guidance, and 8 further topics. 12 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition of non-muscle-invasive bladder cancer

> “Urothelial tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system”
> “Intra-epithelial, high-grade (HG) tumours confined to the mucosa are classified as CIS (Tis).”
> “All of these tumours can be treated by transurethral resection of the bladder tumour (TURBT), eventually in combination with intravesical instillations, and are therefore grouped under the heading of NMIBC for therapeutic purposes.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-2"></a>

### Definition and clinical classification of carcinoma in situ

> “Carcinoma in situ is an intra-epithelial, HG, non-invasive UC.”
> “Primary: isolated CIS with no previous or concurrent papillary tumours and no previous CIS.”
> “Secondary: CIS detected during follow-up of patients with a previous tumour that was not CIS.”
> “Concurrent: CIS in the presence of any other urothelial tumour in the bladder.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-3"></a>

### High-risk and very high-risk NMIBC: EAU prognostic factor risk groups

> “All T1 HG/G3 without CIS, EXCEPT those included in the very high-risk group”
> “All CIS patients, EXCEPT those included in the very high-risk group”
> “Additional clinical risk factors are age > 70; multiple papillary tumours; and tumour diameter > 3 cm.”
> “T1 HG/G3 and CIS with at least one risk factor”
> “Patients with primary (pure) CIS should be considered in the high-risk group.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-4"></a>

### Definition of BCG-unresponsive disease: FDA guidance

> “For the purposes of this guidance, BCG-unresponsive disease is defined as being at least one of”
> “Persistent or recurrent Carcinoma in Situ (CIS) alone or with recurrent”
> “(noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease”
> “within 12 months of completion of adequate BCG therapy”
> “disease within 6 months of completion of adequate BCG”
> “T1 high-grade disease at the first evaluation following an induction BCG”
> “At least five of six doses of an initial induction course plus at least two of three doses of”
> “At least five of six doses of an initial induction course plus at least two of six doses of a”
> “Patients with BCG-unresponsive NMIBC are unlikely to benefit from further therapy with BCG”
> “Patients with BCG-unresponsive NMIBC include those who experienced recurrence with either”
> “papillary disease or CIS or both and who have completely resected disease, resected disease with”
> “CIS, or CIS alone at trial entry.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-2.2.1.1-5"></a>

### Categories of BCG failure: EAU definitions

> “Several categories of BCG failures, broadly defined as any HG disease occurring during or after BCG therapy, have been proposed (see Table 7.2).”
> “To be able to specify the subgroup of patients where additional BCG is unlikely to provide benefit, the category of BCG-unresponsive tumour was defined. Further BCG instillations in these patients are associated with an increased risk of progression”
> “The category of BCG-unresponsive tumours comprises BCG-refractory and early BCG-relapsing tumours (see Table 7.2)”
> “BCG-unresponsive tumours include all BCG refractory tumours and those who develop T1/Ta HG recurrence within six months of completion of adequate BCG exposure”
> “or develop CIS within 12 months of completion of adequate BCG exposure”
> “Adequate BCG is defined as the completion of at least five of six doses of an initial induction course plus at least two out of six doses of a second induction course or two out of three doses of maintenance therapy.”
> “Non-HG recurrence after BCG is not considered as BCG failure.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-6"></a>

### BCG-exposed disease: high-grade recurrence outside the BCG-unresponsive criteria

> “Patients who experience recurrence with HG NMIBC after BCG without meeting BCG-unresponsive criteria may benefit from additional BCG therapy. This category of high-risk patients that lies between BCG-naïve and BCG-unresponsive NMIBC is termed BCG-exposed”
> “Delayed relapse after adequate BCG: to indicate patients that are disease free after adequate BCG but subsequently experience a HG recurrence outside of the BCG-unresponsive window (> 6 months for Ta/T1 and > 12 months for CIS), up to 24 months.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.1-7"></a>

### International Bladder Cancer Group classification of BCG failures

> “Table 5 summarizes our classification of BCG failures, dividing them into the following four types: BCG refractory, BCG relapsing, BCG intolerant, and BCG unresponsive.”
> “Persistent high-grade disease at 6 months despite adequate BCG”
> “The term BCG unresponsive, which essentially includes BCG refractory and BCG relapsing (within 6 months of last BCG exposure), is meant to denote a subgroup of patients at highest risk of recurrence and progression for whom additional BCG therapy is not a feasible option.”
> “For clinical trials, adequate BCG therapy is when a patient has received at least five of six induction instillations and at least one maintenance (two of three instillations) in a 6-month period.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-2.2.1.1-8"></a>

### Origin of the term BCG-unresponsive: 2015 Genitourinary Cancers Symposium task force

> “identifies those patients with high grade (HG) NMIBC who have been treated with adequate BCG (see below) and are unlikely to benefit from and should not receive further intravesical BCG.”
> “Have received at least 2 courses of intravesical BCG – defined as at least 5 of 6 induction instillations of BCG and at least 2 of 3 instillations of maintenance BCG.”
> “Exception: those who have T1HG disease at first evaluation following induction BCG alone (at least 5 of 6 doses) would qualify.”
> “We also recommend including CIS of the prostatic urethra within the definition of BCG unresponsive”

Source: [Lerner et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4720147/)

<a id="topic-2.2.1.1-9"></a>

### Data-driven definition of BCG-unresponsive disease

> “Those with CIS recurrence at 6–12 months did not differ from those recurring within 6 months (HR = 0.88, p = 0.71).”
> “Patients who fail two courses of BCG with either persistent or recurrent multifocal papillary disease within 6 months or CIS within 12 months of their prior BCG should be considered BCG unresponsive.”

Source: [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)

<a id="topic-2.2.1.1-10"></a>

### Etiology of bladder cancer: tobacco smoking

> “Tobacco smoking is the most important risk factor for BC, accounting for approximately 50% of cases”
> “The risk of BC increases with smoking duration and intensity”
> “Passive exposure to tobacco smoke is also associated with an increased risk of BC”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “It is estimated that cigarette smoking causes up to one-half of all bladder cancers and that smoking increases a person’s risk of bladder cancer two to four times above baseline risk.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

> “Advanced age, male sex, and cigarette smoking contribute to the development of bladder cancer.”

Source: [Lenis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33201207/)

<a id="topic-2.2.1.1-11"></a>

### Etiology of bladder cancer: occupational, environmental, and treatment-related exposures

> “Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for BC, accounting for approximately 10% of all cases.”
> “Exposure to pelvic ionising radiation is associated with an increased risk of BC”
> “Schistosomiasis, an infection caused by a parasitic trematode, can lead to BC”
> “A weak association was also suggested for cyclophosphamide and pioglitazone”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Specific chemicals linked to bladder carcinogenesis include beta-naphthylamine, 4-aminobiphenyl, and benzidine.”
> “Exposure to the chemotherapy drug cyclophosphamide has also been associated with an increased risk of bladder cancer.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.1-12"></a>

### Etiology of bladder cancer: genetic factors

> “Family history appears to have little impact”
> “Lynch syndrome carriers appear to have a higher relative risk of developing BC”
> “Currently, there is insufficient evidence to support genetic screening for BC.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
